Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bonny Moore (NPI 1902048051)

Field	Value
Entity Type	Individual
Organization	Bonny Moore
Address	4501 Empire Ct
City	Fredericksburg
State	VA
ZIP	22408
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 2, 2009

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider is a hematology & oncology physician in FREDERICKSBURG, VA with an NPI enumerated on 2009-04-02 (~17 years ago), indicating long-standing Medicare participation and sustained presence in oncology care delivery at the practice level. The tenure suggests established referral relationships and continuity of care for complex cancer patients.

Lifetime Medicare revenue is listed as $2.7M while there is no Medicaid billing on file; the provider’s book of business is effectively single-payer (Medicare) in the available data, so Medicaid does not meaningfully factor into payer-mix or state-level competitive analysis for this NPI.

Revenue concentration is high: the precomputed top three Medicare codes by revenue account for 50.4% of this provider’s total Medicare revenue, indicating the practice depends heavily on a small number of high-cost oncology drug administrations and related services for its Medicare income. This level of concentration suggests a focused oncology infusion practice rather than a broad primary-care panel.

The single largest Medicare revenue driver is J9271 (pembrolizumab) at $722.4K, which alone represents 28.2% of total Medicare revenue; paired with J9144 (daratumumab) at $294.1K and J9299 (nivolumab) at $273.6K, the top three are biologic/immunotherapy infusions and together make up the precomputed 50.4% share. This code mix points to a service line centered on high-cost monoclonal antibody and immunotherapy administration.

Competitive standing varies by code: for J9271 the provider ranks #568 of 1841 (69th percentile), a fairly typical national volume for that immunotherapy; J9144 ranks #320 of 615 (46th percentile) and J9299 ranks #314 of 505 (38th percentile), both indicating modest-to-typical participation nationally rather than market dominance in those agents. In contrast, for some supportive or adjunctive products the provider appears unusually active.

Several codes are statistical outliers on the high side: J0897 (denosumab) ranks in the 94th percentile nationally and J1439 (ferric carboxymaltose) ranks in the 96th percentile, both described as notably above typical national volume — this suggests the provider administers more bone-targeted therapy and IV iron than most peers, which may reflect the specific oncology subpopulations treated (e.g., bone metastases, chemotherapy-associated iron deficiency).

Procedure-level billing shows that routine oncology practice workflows are present: E/M office visit codes 99214 and 99215 together contribute meaningful revenue ($102.1K and $43.6K respectively) with 99214 noted as an extreme outlier (98th percentile) for volume, implying a high number of established outpatient evaluations in addition to infusion care. This mix supports an integrated clinic model that combines consultations/management with in-office infusions.

Infusion and chemotherapy administration codes (96413, 96365, 96367) and supportive drug codes (J2506 pegfilgrastim, Q5119 rituximab biosimilar, Q5114 trastuzumab biosimilar) appear throughout the top revenue list at typical-to-high percentiles, reinforcing that the practice workload is dominated by in-office infusion services and oncology supportive care rather than diagnostic-only activity. These patterns are consistent with a community oncology infusion center model.

Given the lack of Medicaid activity and the Medicare-focused revenue profile, payer negotiations or network strategy should treat this NPI as heavily Medicare-dependent; any expansion into Medicaid-managed-care populations would represent a material change from the current documented billing footprint and should be evaluated separately from these Medicare-derived signals.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

87 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	16,800	$40	$722.4K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,740	$40	$294.1K
J9299	Injection, nivolumab, 1 mg	11,400	$20	$273.6K
J0897	Injection, denosumab, 1 mg	14,100	$20	$253.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,600	$40	$237.6K
J1930	Injection, lanreotide, 1 mg	3,840	$40	$165.1K
J1439	Injection, ferric carboxymaltose, 1 mg	107,250	$1	$107.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,110	$90	$102.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	490	$100	$48.4K
Q5114	Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg	1,450	$30	$46.5K

Showing 1–10 of 87

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Bonny Moore — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

87 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	29	110	12,800	$40	$610.9K
J9299	17	30	12,920	$20	$335.4K
J9144	30	60	8,280	$40	$332.7K
J1930	4	10	3,840	$40	$188.7K
J1569	3	30	3,000	$40	$135.7K
J0897	17	340	2,820	$20	$89.3K
Q5119	14	40	1,570	$20	$39.6K
Q5114	1	10	1,160	$30	$37.4K
88185	12	60	620	$20	$34.3K
Q5122	21	40	270	$90	$32.5K

Showing 1–10 of 87

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bonny Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
American Oncology Partners PA	OH	Hematology & Oncology Physician	$0	$11.8M
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
David Smith	MD	Hematology & Oncology Physician	$6.4M	$0
Stephen Divers	AR	Hematology & Oncology Physician	$3.9M	$1.5K
Robert Muldoon	AR	Hematology & Oncology Physician	$3.2M	$0
Bradley Sumrall	GA	Medical Oncology Physician	$3.1M	$0
Linda Hendricks	GA	Specialist	$3.1M	$0

Nearby Providers

Other providers in the same ZIP code as Bonny Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Compass Counseling Services Of Northern Virginia	VA	Community/Behavioral Health Agency	$0	$54.4M
Spotsylvania Medical Center Inc	VA	General Acute Care Hospital	$0	$31M
Pinnacle Treatment Centers Va-i, LLC	VA	Methadone Clinic	$152.9K	$15.6M
Assured Corporation	VA	Home Health Agency	$0	$12.8M
Lakshminarayanan Nandagopal	VA	Hematology & Oncology Physician	$2.9M	$0
Charles Maurer	VA	Hematology & Oncology Physician	$2.8M	$0
Matthew Whitehurst	VA	Medical Oncology Physician	$2.1M	$0
Sudeep Menachery	VA	Hematology & Oncology Physician	$1.9M	$0
Arijit Chanda	VA	Interventional Cardiology Physician	$571.6K	$0
Anh Vu	VA	Cardiovascular Disease Physician	$549.9K	$90

Bonny Moore — Billing Profile & Reimbursement Data

Sign up for Bonny Moore — Billing Profile & Reimbursement Data policy alerts

Bonny Moore — Billing Profile & Reimbursement Data

Sign up for Bonny Moore — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References